Abstract：Objective: To investigate the expression of 5-HT, DA, INH and NE in patients with depression after escitalopram treatment, and to provide the basis for clinical application. Methods: 50 cases of patients with depression admitted from June 2014 to January 2015 in our hospital were analyzed, using escitalopram to intervene; analysed live full brain, around the central, frontal, occipital, left and right around the left and right top, left temporal and other areas of the brain in 5-HT, DA, INH, NE induced analysis before and after treatment, patients with clinical treatment records. Results: The clinical effective rate was 92% after treatment with escitalopram; the 5-HT of the whole brain, right, right, right and right anterior temporal regions were significantly reduced, after treatment and the difference was statistically significant (P<0.05); The DA levels in the whole brain, right frontal, right central, right top, right anterior temporal area were significantly increased, and the difference was statistically significant (P<0.05); The INH level in the left frontal area was significantly lower (P<0.05); The left central part and right central NE levels were significantly lower (P<0.05); and the NE levels in the left and right occipital regions were significantly higher (P<0.05). Conclusion: After the treatment with escitalopram, the clinical effect of the patients with depression is good, and it can effectively correct the abnormal expression of 5-HT, DA, NE, and INH in each brain region.
万姝. 艾司西酞普兰对抑郁症患者各脑区5-HT DAINH NE表达的影响研究[J]. 河北医学, 2017, 23(5): 712-715.
WAN Shu. The Effect of Escitalopram on the Expression of 5-HT DA INH and NE in Different Brain Regions of Patients with Depression. 河北医学, 2017, 23(5): 712-715.
[1] Pastoor D,Gobburu J.Clinical pharmacology review of escitalopram for the treatment of depression[J].Expert Opinion on Drug Metabolism,2014,10(1):121~128. [2] Nehama Y,Rabinowitz I,Baruch Y,et al.Debunking the placebo effect in depression:The effect of patient and investigator expectation on escitalopram efficacy[J].International Clinical Psychopharmacology,2014,29(2):106~110. [3] 李英辉,卢娜,张钰群,等.艾司西酞普兰与度洛西汀对抑郁症患者述情障碍疗效的对比研究[J].东南大学学报(医学版),2015,34(6):971~975. [4] DeBerardis D,Serroni N,Marini S,et al.Emerging mania following escitalopram withdrawal in a patient with unipolar depression managed with its reintroduction[J].Journal of Psychiatric Practice,2014,20(3):228~231. [5] 李则挚,彭代辉,黄佳,等.国产与进口文拉法辛对抑郁症患者汉密尔顿抑郁及焦虑量表因子分影响的比较[J].中国神经精神疾病杂志,2012,38(12):760~763. [6] 陈彦方.关于《中国精神障碍分类与诊断标准第三版》的几个问题[J].中华精神科杂志,2001,34(3):6~8. [7] Myslobodsky M S,Coppola R,Bar-Ziv J,et al.Adequacy of the International 10-20 electrode system for computed neurophysiologic topography[J].Journal of Clinical Neurophysiology,1990,7(4):507~518. [8] Mischoulon D,Price L H,Carpenter L L,et al.A double-blind,randomized,placebo-controlled clinical trial of S-Adenosyl-L-Methionine(SAMe)versus escitalopram in major depressive disorder[J].The Journal of Clinical Psychiatry,2014,75(4):370~376. [9] 苏凡,易宏伟,张志珺,等.选择性5-羟色胺再摄取抑制剂对小胶质细胞不同活化途径的影响[J].中华精神科杂志,2014,47(6):364~370. [10] Doron R,Lotan D,Einat N,et al.A novel herbal treatment reduces depressive-like behaviors and increases BDNF levels in the brain of stressed mice[J].Life Sciences,2014,94(2):151~157. [11] Schramm,Elisabeth,Zobel,et al.Cognitive behavioral analysis system of psychotherapy versus escitalopram in chronic major depression[J].Psychotherapy and Psychosomatics,2015,84(4):227~240. [12] 周会.雌激素替代疗法及心理放松疗法结合艾司西酞普兰对围绝经期中重度抑郁症状的影响[J].河北医学,2016,22(3):481~483. [13] Laux G,riede M,Müller W E,et al.Treatment of comorbid anxiety and depression with escitalopram:results of a post-marketing surveillance study[J].Pharmacopsychiatry,2013,46(1):16~22. [14] Jaracz,Jan,Gattner,Karolina,Moczko,Jerzy, et al.Comparison of the effects of escitalopram and nortriptyline on painful symptoms in patients with major depression[J].General Hospital Psychiatry,2015,37(1):36~39.
2017, Vol. 23 
冀公网安备13080202000677号